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Abstract 
The present study aimed to explore the predictors of weight loss following orlistat with a 
focus on both baseline variables and changes in beliefs and behaviours occurring over the 
course of taking the drug.   Patients (n=566) prescribed orlistat completed a questionnaire 
at baseline and after 6 months concerning their weight, beliefs and behaviours.   The 
results showed that by 6 months the majority had lost weight and showed improvements 
in diet.  Many had also stopped taking the drug and a large minority reported using it 
flexibly as a lifestyle drug.   The results also showed that those who lost most weight 
showed a decrease in beliefs in a medical solution, a decrease in unhealthy eating, an 
increased belief in treatment control and an increased belief that the unpleasant 
consequences are both due to their eating behaviour and just part of the drug.   When 
taken with high fat food orlistat causes symptoms such as anal leakage and oily stools as 
it removes dietary fat from the body.   It is argued that such consequences may encourage 
some patients to focus on the behavioural aspects of their weight problem thus promoting 
the dietary changes needed for both short and longer term weight loss.  When prescribing 
orlistat, clinicians should encourage patients to see the consequences as an education as a 
means to promote the effectiveness of this form of medical management.   
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Introduction  
Orlistat (Xenical) is currently the only available form of prescribed obesity medication 
which acts on the gastrointestinal system and works by reducing fat absorption in the gut 
which is eliminated in bowel movements.  It also blocks the availability of fat soluble 
vitamins (vitamins A, D, E and K) so patients may also take a vitamin supplement [1, 2].   
Current recommendations suggest that it is used for patients who have a history of failed 
weight loss attempts using behavioural methods and who can demonstrate at least 2.5kg 
weight loss by diet and exercise in the month prior to their first prescription [1]. It is 
suggested that patients reduce their daily calorie intake by 500 to 1000 calories to 
promote weight loss and the Dietary Guidelines for Americans recommend that dietary 
fat is limited to about 30% of daily calories.   As a result of its impact upon fat absorption 
orlistat has unpleasant side effects including liquid stools, an urgency to go to the toilet 
and anal leakage which are particularly apparent following a high fat meal as the drug 
causes the fat consumed to be removed from the body.   Between 1998 and 2005, orlistat 
prescriptions rose 36-fold from 17,880 to 646,700 and the total cost increased by over 35-
fold.  Recent years have seen an additional significant increase in the number and cost of 
prescriptions for orlistat [3]. 
 
Research has explored the effectiveness of orlistat compared either to other drug 
treatments, placebo or behavioural focused interventions.  For example, Padwal, Li and 
Lau [4] reported that patients taking orlistat lost 2.7kg more than patients taking placebo 
and Avenell et al [5] carried out a systematic review of trials involving a combination of 
diets, drug therapy, exercise and behaviour therapy and concluded that adding orlistat to a 
dietary intervention improved weight loss by 3.26kg up to 24 months.  Research also 
indicated that orlistat reduces cholesterol and blood pressure levels and improves 
glycemic control when compared to placebo [4].  Similarly, Phelan and Wadden [6] 
concluded from their review that adding orlistat to lifestyle modification interventions 
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improves both weight loss and weight loss maintenance.  Furthermore, in a recent 
updated meta analysis Rucker et al [7] synthesised the results of randomised placebo 
controlled trials of approved anti obesity drugs in adults aged 18 and over for one to four 
years.  They concluded that with the active drug treatments patients were more likely to 
reach 5% and 10% weight loss thresholds and that weight losses for three key drugs were 
as follows: sibutramine: 4.2kg; rimonabant: 4.7kg and orlistat: 2.9kg.  Research therefore 
indicates that orlistat can improve weight loss if used alongside behavioural and lifestyle 
interventions. 
 
There remain however, two main problems with orlistat as a treatment for obesity.  First, 
although evidence indicates that it can improve weight loss outcomes, these 
improvements are not always substantial and there is much variability with many patients 
showing no improvements at all.   Second, research also indicates high attrition rates with 
patients not adhering to their medication due to the unpleasant side effects and many 
stopping taking the drug entirely or using it selectively according to the content of their 
diet.  For example, Padwal, Li and Lau [4] concluded from their review of randomised 
control trials that the mean attrition rate for orlistat was 33% (11 studies, n=6021) and 
Vray et al [8] suggested that in clinical practice attrition rates are even higher at 64-77%.   
Research has therefore addressed whether the effectiveness of orlistat can be improved 
and some studies have explored whether specific patients benefit more than others and 
whether baseline variables predict outcomes.   However, whereas research exploring 
alternative forms of medical management has explored a range of clinical, psychological 
and behavioural variables as predictors of outcomes [eg. 9-11] research focusing on 
orlistat has mainly emphasised laboratory and clinical variables [12].  In general, 
however such studies conclude that the best predictor of outcome following medical 
management is initial weight loss but to date few studies have explored psychological 
and behavioural predictors of outcome following orlistat.  An alternative approach has 
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addressed the mechanisms of how orlistat works and from a medical perspective the 
main consequence of orlistat is to reduce fat absorption in the gut.  However, due to the 
unpleasant side effects Finer has labelled it the antabuse effect [13] as it deters the intake 
of high fat foods.  Further, Ogden and Sidhu [14] carried a qualitative study with patients 
who had taken orlistat to explore their beliefs about why it either did or did not facilitate 
weight loss.  The results showed that in line with previous research some patients stopped 
taking their medication due to the unpleasant symptoms such as anal leakage or oily 
stools.  However, the results also showed that these highly visual side effects encouraged 
some people to consider their behaviour as a cause of their obesity.  Many obese people 
focus on medical causes of their problem such as hormones and genetics [15, 16].  The 
results from this qualitative study of orlistat users indicated that by showing patients the 
fat they have consumed, orlistat can shift patient models of obesity towards a more 
behavioural perspective thus encouraging them to adopt a healthier diet.   Leventhal and 
colleagues [17] described the notion of coherence between beliefs about causes and 
solutions to any particular medical problem.   In line with this, Ogden and Sidhu [14] 
argued that orlistat functions by educating patients and creating coherence between 
behavioural causes and therefore behavioural solutions for obesity.  To date however this 
process remains untested in a larger quantitative study. 
 
In summary, although orlistat is currently the most commonly prescribed medication for 
the obese there remains much variability in its effectiveness with only a minority of 
patients showing weight loss.  Research has therefore explored the possible reasons for 
the effectiveness of orlistat and whereas some studies have emphasised baseline 
characteristics, others have highlighted changes in beliefs and behaviour brought about 
by the mechanisms of the drug itself. To date however such studies have focused either 
on drugs other than orlistat, been limited in their choice of variables or used small 
qualitative designs. The present study therefore aimed to explore weight loss following a 
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6 month course of orlistat and to explore the role of demographics, beliefs and 
behaviours in predicting outcomes in a large sample of patients.  Furthermore, in line 
with a focus on mechanisms, the study aimed to assess the role of both baseline variables 
and the changes occurring whilst orlistat was being taken. 
 
Method 
Design 
The study used a longitudinal design with measures concerning BMI, experiences of 
taking orlistat and beliefs and behaviours being completed at baseline and six months 
follow up. 
 
Sample 
Participants who had been prescribed orlistat by the GP and registered on the Xenical 
support system (MAP) funded by Roche were invited to take part in the study and sent 
the baseline questionnaire.  Those who returned the baseline questionnaire were sent a 
further questionnaire at six months. Only those who completed the baseline questionnaire 
within the first three months of starting to take the medication and returned the 6 month 
follow up questionnaire were included in this study. 566 participants returned both the 
baseline questionnaire within the first three months of them starting to take orlistat and 
the 6 month follow up questionnaire.  This represented a response rate of 36% of total 
baseline responders. The University Ethics committee approved the study. The data 
presented here reflects the short term follow up from baseline to six months.   
 
Procedure 
MAP gained initial consent from participants to pass on their contact details to take part 
in the study. An information sheet and questionnaire were then sent out to participants by 
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post.  Those who returned the baseline questionnaire were sent a similar follow up 
questionnaire at six months. 
 
Measures 
Baseline and follow up questionnaires examined demographics, beliefs about obesity, 
beliefs about side effects and behaviours.  All beliefs and behaviours were assessed using 
items which were rated using a 5 point Likert scale ranging from ‘Not at all’ (1) to 
‘Totally’ (5).   For each construct the individual items were summated and the reliability 
of each construct was assessed using Cronbach’s alpha.  Most alphas were above the 
established cut off level illustrating acceptable reliability.  Some were lower but this is 
generally acceptable if there is diversity in the constructs being measured.   
 
1.Demographics: participants completed measures of weight, height, BMI, age, sex, 
employment. 
2.Beliefs about obesity: this included measures relating to i) behavioural causes of 
obesity (α=.671) (eg. ‘Eating too much’, ‘not enough exercise’); ii) medical causes of 
obesity (α=.659) (eg. ‘Genetics / inheritance’, ‘slow metabolism’); iii) behavioural 
solutions to obesity (α=.850) (eg. ‘Eating fewer calories’, ‘being more active’); iv) 
medical solutions to obesity (α=.630) (eg. ‘Medication’, ‘surgery’); v) personal control 
over weight (eg. ‘How much control do you think you have over your weight’); iv) 
treatment control over weight (eg. ‘How much do you think Xenical can help your 
weight?’).  
3.Beliefs about side effects: participants rated the extent to which; i) they had 
experienced side effects (α=.761) (eg. ‘Liquid stools’, ‘bloating’); ii) they believed these 
side effects were part of the drug (α=.671) (eg. ‘They are a necessary part of taking the 
drug’) and ii) whether the side effects were caused by eating behaviour (α=.826) (eg. 
‘They have made me realise what is in different foods’).  
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4.Behaviours:  participants rated their behaviour in terms of i) adherence to 
medication (α=.577) (eg. ‘I take it religiously’, ‘I stop taking it before a fatty meal’ 
(which was reversed scored)), ii) healthy eating (α=.580) (eg. Healthy snacks (eg. rice 
cakes, crackers, fruit), healthy cooking (eg. Boil, steam, cooked meals at home’), healthy 
food choices (eg. Skimmed milk, low fat cheese, high intake of fruit and vegetables’)) ii) 
unhealthy eating (α=.547) (eg. Unhealthy snacks (eg. Crisps, cakes, chocolate), 
unhealthy cooking (eg. Shallow fry, deep fry, processed foods), unhealthy food choices 
(eg. Full cream milk, full fat butter / margarine, low intake of fruit and vegetables)). 
 
All measures related to the PAST MONTH and were based on previous qualitative 
research which has explored people’s beliefs and experiences of taking obesity 
medication and successful weight loss and maintenance [14, 18].   Participants also 
completed the personal and treatment control items of the brief Illness Perception 
Questionnaire that assesses participants’ beliefs about their illness [19].  In addition the 
healthy and unhealthy eating measures were taken from the World Health Organisation 
2001/02 protocol [20], the food frequency questionnaires found in Inchley et al [21], the 
seven day food diary [22] and consumer market research report data [23]. 
 
Inclusion/Exclusion Criteria 
Participants were included if they registered with the MAP program within a four month 
period, were 18 years or over and had been prescribed orlistat by their GP and if they had 
completed the baseline questionnaire within the first three months of starting to take 
orlistat and also returned the follow up questionnaire at six months. 
 
Data analysis  
The data were analysed to describe the participants’ demographics, differences between 
responders and non-responders and overall changes in BMI, weight and behaviour.  
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Further, the data were analysed to assess the role of baseline demographics, beliefs and 
behaviour in predicting improvements in BMI, and to assess the role of changes in beliefs 
and behaviour over the course of 6 months in predicting improvement in BMI by 6 
months.   
 
Results 
1. Participants’ demographics and responders vs non responders 
Responders’ to the questionnaire vs non responders’ (at 6 months) demographic variables 
are shown in Table 1.   
-Insert table 1 about here - 
 
The results showed that the mean age of the people who returned a completed 
questionnaire at both time points (responders) was 50 years and that the majority were 
white, female, not working, married, educated up until college with a mean BMI of 36.  
Further, the responders and non responders (those who returned the baseline 
questionnaire but not the follow up questionnaire at 6 months) were comparable on all 
baseline demographics apart from age with the responders being older than the non 
responders. 
 
2. Overall changes in BMI, weight and behaviour 
Change scores for BMI, beliefs and behaviour were calculated (T1-T2) and then 
classified into groups:  weight loss vs no weight loss; decrease in BMI vs no decrease in 
BMI; improvement in healthy eating vs no improvement; increased unhealthy eating vs 
no increase and for adherence those who had stopped taking it by 6 months were grouped 
as ‘non adherers’, those who rated their adherence as ‘totally’ were rated as ‘adherers’ 
and those who reported flexible adherence according to what they were eating were 
recoded as ‘lifestyle adherers’.   These results are shown in Table 2.  
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-insert table 2 about here - 
 
The results showed that by 6 months the majority of the responders had lost weight and 
decreased their BMI.  The mean weight loss was 4.09kg (SD: 6.21), the median weight 
loss was 3.63kg and percentage weight losses were as follows: 0-2kg: 19.36%; 2.1-5kg: 
28.1%; 5.1-7kg: 15.9kg; 7.1-10kg: 17.4%; 10.1+kg: 19.3%.  In addition, the majority had 
increased their healthy eating and decreased their unhealthy eating and were no longer 
taking orlistat although a large minority reported either full adherence or being lifestyle 
users by 6 months.    
 
3. Predictors of improvement in BMI over 6 months.   
The results were then analysed to assess the role of beliefs and behaviours in predicting 
an improvement in BMI by 6 months both in terms of baseline and change scores using 
Multiple Regression analysis using forced entry method. 
 
i)Baseline predictors of BMI improvement. 
The role of baseline beliefs and behaviours in predicting improvements in BMI are 
shown in table 3. 
-insert Table 3 about here – 
The results showed that an improvement in BMI was predicted by a greater endorsement 
of a medical solution to their weight problem at baseline accounting for 7.9% of the 
variance (F=2.862, P=.001).  No other baseline variables were significant. 
 
ii) Changes in beliefs and behaviour as predictors of BMI improvement. 
Changes scores in beliefs and behaviours were calculated (T1-T2).  The role of these 
variables in predicting improvements in BMI is shown in Table 4. 
-Insert Table 4 about here – 
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The results showed that a decrease in BMI over 6 months was predicted by a decrease 
in endorsing a medical solution to their weight problem, a decrease in unhealthy eating, 
an increased belief in treatment control and an increased belief that the side effects are 
both due to their eating behaviour and just part of the drug, accounting for 17.3% of the 
variance (F=4.015, P=.0001). 
 
Discussion 
The present study aimed to explore the predictors of weight loss following 6 months after 
being prescribed orlistat with a focus on both baseline variables and changes in beliefs 
and behaviours over the course of taking the drug. 
 
The results showed that by the end of 6 months three quarters of patients reported both 
weight loss and a reduction in their BMI with the majority falling within the expected 
range in line with previous outcome studies [4, 5, 7].  The majority also reported an 
increase in healthy eating and a decrease in unhealthy eating which reflects the impact of 
orlistat on diet and its use as the ‘antabuse effect’[13].  Furthermore, just under half had 
stopped taking their medication by 6 months and a large minority reported using it 
flexibly in response to their dietary choices which is consistent with high attrition rates 
found in previous studies and the use of orlistat as a lifestyle drug [4, 8].   
 
In terms of predictors of outcomes, only one baseline variable was related to a reduction 
in BMI by six months.  In particular, the results showed that a greater endorsement of a 
medical solution to obesity predicts a greater reduction in BMI by follow up indicating 
that those who have greater expectations of success for the drug show greater 
improvements.  This finds reflection in the focus on baseline predictors reported for other 
forms of medical management [eg. 9; 10] but suggests that it would be difficult to profile 
those patients at baseline who would most benefit from taking the drug.  
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The data were also analysed, however, to explore the role of changes in beliefs and 
behaviours over the course of taking orlistat and produced more promising results.  In 
particular, those who lost most weight showed a decrease in beliefs in a medical solution, 
a decrease in unhealthy eating, an increased belief in treatment control and an increased 
belief that the side effects are both due to their eating behaviour and just part of the drug.   
Therefore, it would seem that taking orlistat may encourage patients to focus on their 
behaviour rather than medical factors as the solutions to obesity and subsequently 
improve their diet and that if such changes in beliefs and behaviour occur, weight loss is 
greater.  This provides quantitative support for previous smaller scale qualitative research 
[14] and indicates that the highly visual side effects of orlistat, while being unpleasant 
and a deterrent for some users, for others may help educate them towards a more 
behavioural focus for their weight problem. 
 
There are some problems with the study which need to be addressed.  First the study did 
not include a control group as the study aimed to explore the predictors of outcomes after 
taking orlistat rather than to assess the effectiveness of this drug.  The effectiveness of the 
drug has been explored elsewhere [4].   Second, both diet and weight were assessed using 
self report rather than an objective measurement tool.  This means that there may well be 
inaccuracies in the data as research has shown that people tend to under estimate both 
their weight and what they eat.  However, for the present study such self report measures 
represented the best means of measuring these variables in a large scale nationwide 
survey as it would not have been feasible to call all participants into the clinic to collect 
more objective data.  Third, the baseline data is not a true baseline in that it did not assess 
participants on the day they first started to take orlistat. Due to the recruitment procedure, 
participants were generally completing the questionnaires within the first 3 months of 
them taking orlistat.  The baseline data therefore reflects their beliefs and experiences at 
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the start of their course of taking orlistat but does not reflect either before or the very 
start of this process.  Future research should aim to recruit participants just before they 
take their first prescription of orlistat in order to gain a true baseline.  Finally, the data 
does not show exactly when the participants stopped taking orlistat.  However, by follow 
up it is known whether the participants were currently taking the drug, or if they had 
stopped within the last month.  Therefore although we do not have an exact marker of 
when the course of medication of was stopped and therefore when its impact upon beliefs 
and behaviour ceased to occur, we do have an approximate measure which enables some 
assessment of the inter relationships between drug use and beliefs and behaviour change.  
Given these limitations, however, the study does provide some insights into the 
mechanisms of orlistat with a focus on the role of beliefs and behaviours in predicting 
weight loss. 
 
Conclusions 
To conclude, orlistat is currently the only prescribed obesity medication available for 
obese patients.  Although research indicates that it can promote weight loss there remains 
problems with adherence and much variability in patient outcomes.   The present study 
aimed to explore predictors of outcomes as a means to improve its effectiveness.   The 
results indicate that changes in beliefs and behaviours occurring throughout the course of 
taking orlistat are the best predictors of outcomes rather than baseline variables.   Further, 
the results indicate that those patients who show a shift away from a medical model of 
their problem towards a focus on their own behaviour and show improvements in their 
diet lose more weight.  These results have implications for patient management and the 
use of orlistat for weight loss.  In particular, orlistat causes unpleasant side effects which 
may cause non adherence.  However, rather than conceptualising such side effects as 
unfortunate they may be the very ‘active’ ingredient necessary to bring about change in 
patients’ behaviour.   Therefore when prescribing orlistat clinicians should not only alert 
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patients to the possibility of such consequences of eating high fat foods, but encourage 
them to focus and learn from them in terms of what they are eating, what this looks like 
when it is excluded from their bodies and what this would do to their bodies if it had 
remained inside.  Such an emphasis may encourage patients to see these consequences of 
the drug, if they eat a diet high in fat, as an education, thus enabling them to take more 
ownership of their weight problem, in turn facilitating and promoting the changes in 
eating behaviour necessary for both short and longer term weight loss and maintenance.   
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Table 1:  Responders vs non-responders at baseline 
 
Variable Responders (n=568) Non-responders (n=1008) t / χ 2 p 
Age x = 50.24 
SD = 13.01 
n = 560 
x = 47.60 
SD = 13.11 
n = 993 
14.59 .0001* 
Sex Male = 98 (17.5%)      
Female = 463 (82.5%) 
Male = 181 (18.1%)      
Female = 817 (81.9%) 
.109 .741 
Ethnicity   White = 543 (97.1%)      
Black Caribbean = 4 (0.7%) 
Black African = 2 (0.4%)      
Asian = 5 (0.9%) 
Other = 5 (0.9%) 
White = 950 (94.8%)      
Black Caribbean=14 (1.4%) 
Black African=7 (0.7%)      
Asian = 16 (1.6%) 
Other = 15 (1.5%) 
4.705 .319 
Job   Full time = 174 (31.6%)      
Part time = 113 (20.5%) 
Not Working = 264 (47.9%) 
Full time = 324 (33.5%)      
Part time = 204 (21.1%) 
Not Working = 439 (45.4%) 
.935 .627 
Marital 
Status   
Married = 330 (59.6%)      
Divorced = 66 (11.9%) 
With Partner = 64 (11.6%) 
Single = 71 (12.8%)      
Widowed = 23 (4.2%) 
Married = 598 (61.5%)      
Divorced = 122 (12.6%) 
With Partner = 98 (10.1%) 
Single = 118 (12.1%)      
Widowed = 36 (3.7%) 
1.370 .849 
Education   < secondary = 68 (12.4%) 
Sec Sch Grad=178 (32.5%) 
Some Coll = 133 (24.3%) 
Coll Grad = 78 (14.3%) 
Graduate = 54 (9.9%)      
Postgraduate = 12 (2.2%) 
Doct/Prof = 24 (4.4%) 
< secondary = 125 (13.2%) 
Sec Sch Grad = 332 (35%) 
Some Coll = 239 (25.2%) 
Coll Grad = 140 (14.8%) 
Graduate = 54 (5.7%)      
Postgraduate = 21 (2.2%) 
Doct/Prof = 37 (3.9%) 
9.525 .146 
BMI x = 36.20                        
SD = 5.84 
n = 527 
x = 35.98                             
SD = 6.01 
n = 948 
.452 .501 
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Table 2: Descriptive analysis of baseline to 6 months data. 
 
 No Yes 
Lose weight n=131    26.4% 
Range = -18 to 0.07 
n=365     73.6% 
Range = 0.08 to 25 
Decrease in BMI n=128    26% 
Range = -6.15 to 0.02 
n=364    74% 
Range = 0.03 to 9 
Increased healthy eating n=187    41.7% 
Range = -8 to 0.07 
n=261    58.3% 
Range = 0.08 to 13 
Increased unhealthy eating n=318    74.1% 
Range = -8 to 0.07 
n=111    25.9% 
Range = 0.08 to 5 
 No Lifestyle Yes 
Adherence n=194 
47.5% 
n=90 
22.1% 
n=124 
30.4% 
 
 
 
 20 
Table 3:  Baseline predictors of a decrease in BMI over 6 months. 
 
Variables Standardised ß 
coefficient 
P 
Age .082 .194 
Sex .072 .234 
Behavioural cause -.100 .161 
Medical cause -.048 .430 
Behavioural solution .078 .267 
Medical solution .157 .012 * 
Treatment control .044 .527 
Personal control .078 .217 
Experience of side effects -.134 .066 
Side effects part of the drug -.001 .984 
Side effects due to eating behaviour -.032 .621 
Healthy diet .018 .766 
Unhealthy diet -.125 .054 
  Adjusted R2  = .079 
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Table 4:  Change scores as predictors of improvements in BMI over 6 months. 
 
Variables Standardised ß 
coefficient 
P 
Change behavioural cause .123 .151 
Change medical cause .013 .866 
Change behavioural solution -.004 .963 
Change medical solution .228 .004 * 
Change treatment control -.259 .001 * 
Change personal control -.052 .498 
Change in experience of side 
effects 
-.020 .810 
Change side effects part of the 
drug 
-.167 .039 * 
Change side effects due to eating 
behaviour 
-.218 .005 * 
Change healthy eating .115 .129 
Change unhealthy eating .183 .017 * 
  Adjusted R2  = .173 
   
 
